Sequential parallel comparison design with two coprimary endpoints. (12th December 2019)

• Record Type: Journal Article
• Authors: Homma, Gosuke; Daimon, Takashi
• Is Part Of: Pharmaceutical statistics. Volume 19:Number 3(2020)
• Page Start: 243
• Page End: 254
• Publication Date: 2019-12-12
• Subjects: bivariate normally distributed endpoint -- enrichment design -- intersection‐union test -- placebo nonresponder -- placebo responder; Pharmacy -- Statistical methods -- Periodicals; Pharmacy -- Statistics -- Periodicals; 615.10727
• DOI: 10.1002/pst.1987
• Languages: English
• ISSNs: 1539-1604

Abstract

Abstract : A placebo‐controlled randomized clinical trial is required to demonstrate that an experimental treatment is superior to its corresponding placebo on multiple coprimary endpoints. This is particularly true in the field of neurology. In fact, clinical trials for neurological disorders need to show the superiority of an experimental treatment over a placebo in two coprimary endpoints. Unfortunately, these trials often fail to detect a true treatment effect for the experimental treatment versus the placebo owing to an unexpectedly high placebo response rate. Sequential parallel comparison design (SPCD) can be used to address this problem. However, the SPCD has not yet been discussed in relation to clinical trials with coprimary endpoints. In this article, our aim was to develop a hypothesis‐testing method and a method for calculating the corresponding sample size for the SPCD with two coprimary endpoints. In a simulation, we show that the proposed hypothesis‐testing method achieves the nominal type I error rate and power and that the proposed sample size calculation method has adequate power accuracy. In addition, the usefulness of our methods is confirmed by returning to an SPCD trial with a single primary endpoint of Alzheimer disease‐related agitation.